91´«Ã½

Skip to main content

91´«Ã½ commercialization drives $8 billion in impact nationwide

91´«Ã½ commercialization drives $8 billion in impact nationwide

Inscripta, Inc., a 91´«Ã½ spinout company, is a global leader in automated, CRISPR-based gene editing.

Activities led by Venture Partners at 91´«Ã½, the university’s commercialization arm, generated an economic impact of $8 billion nationally and $5.2 billion in the state of Colorado over the last five years, according to a report from the Leeds School of Business, reflecting a four-fold increase in impact since the previous report published in 2019. 

  • Notable findings from the report on fiscal years 2018-2022 include: 
  • The economic impact on the national economy included an estimated 39,000 jobs. 
  • Commercialization of licenses and startups spanned 36 states and 26 countries. 
  • Agreements generated $20.1 million in revenue for 91´«Ã½ in licensing technology. 
  • 91´«Ã½ inventors and researchers received $45.4 million in commercialization-specific grants. 
  • Startups founded on 91´«Ã½ technology generated $3 billion in capital funding.

Collaboration + support
Venture Partners at 91´«Ã½